Amgen Inc.

Gordon Ng

Wenyan Shen

Benny C Askew

Chuan-Fa Liu

Derin C D'amico

Mark A Jarosinski

Yue-Sheng Li

Colin V Gegg

Qi Huang

Yuelie Lu

Thomas Storz

Chadwick Terence King

Shaw-Fen Sylvia Hu

David R Martin

Joanne Louise Viney

Hung Q Nguyen

John Peter Geibel

William Gleason Richards

Steven Charles Hebert

Jeannie Jung

Jr Benny C Askew

Liu Chuan-Fa

The present invention provides compositions and methods relating to antigen binding proteins against CCR7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins.

Methods and compositions relating to anti-CCR7 antigen binding proteins

This invention relates to compositions and methods for treating c-Kit associated disorders such as fibrosis, and more particularly, to compositions containing humanized c-Kit antibodies.

Nucleic acid encoding humanized c-kit antibody

This invention relates generally to the field of medicine and, more specifically, to methods for treating epithelial injury, in particular, due to ischemia, hypoxia, trauma, chemolytics or radiation exposure.

Calcimimetic compound for use in the treatment of epithelial injury

Humanized C-kit antibody

The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a univalent vehicle, including peptides conjugated to univalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.

Antagonists of the bradykinin B1 receptor

The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.

Humanized c-Kit antibody

The present invention relates to certain biologically active peptides and conjugated peptides which can be used as therapeutics or prophylactics against diseases or conditions linked to B1 as the causative agent. In a preferred embodiment of the invention biologically active PEG-conjugated peptides are provided. In one aspect of the present invention, pharmacologically active PEG-conjugated peptides of the present invention are useful to treat inflammation or pain.

Antagonists of the brandykinin B1 receptor

Growing community of inventors

Newbury Park, CA, United States of America

Gordon Ng